National Institute for Health and Care Excellence

Photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic skin lesions)

The National Institute for Health and Clinical Excellence is examining photodynamic therapy for photodynamic therapy for non-melanoma skin tumours (including premalignant and primary non-metastatic ...
The American Journal of Managed Care

Patients With Actinic Keratosis Prefer Simulated Daylight PDT Over More Painful Red Light PDT

A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient ...
Cure Today

Early Data Show Benefits With Ameluz-Photodynamic Therapy in Skin Cancer Subset

Ameluz-based photodynamic therapy achieved higher clearance rates in superficial basal cell carcinoma compared to placebo, with significant clinical and histological results. The study involved 187 ...
Seeking Alpha

Biofrontera Inc. Announces Filing of Supplemental New Drug Application (sNDA) for the Treatment of Superficial Basal Cell Carcinoma (sBCC) with Ameluz®-PDT

WOBURN, Mass., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
Medical Xpress

Treating tumors independently of oxygen: Photodynamic therapy uses hydrogen peroxide instead

Photodynamic treatment of cancer is based on administering an initially inactive substance that is only activated in the tumor via targeted light irradiation. It then generates reactive oxygen species ...
Nasdaq

Biofrontera Inc. Announces Database Lock Of Phase 3 Study Of Ameluz®-Photodynamic Therapy (PDT) In The Treatment Of Superficial Basal Cell Carcinoma (sBCC)

WOBURN, Mass., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...
Seeking Alpha

Biofrontera Inc. Announces Last Patient Out in Phase 3 Study of Ameluz® (aminolevulinic acid HCI) Topical Gel, 10% Photodynamic Therapy (PDT) for the Treatment of Actinic ...

WOBURN, Mass., Sept. 16, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (BFRI) (“Biofrontera” or the “Company”), a biopharmaceutical company specializing in the development and commercialization of ...